Research & Literature

Hepatitis B Virus and Hepatitis D Virus Entry, Species Specificity, and Tissue Tropism.

Watashi K, Wakita T

Cold Spring Harbor perspectives in medicine 2015; (5(8)):a021378.

Hepatitis delta virus: From biological and medical aspects to current and investigational therapeutic options.

Alfaiate D, Dény P, Durantel D

Antiviral research 2015; (122()):112-29.

Hepatitis D Virus Replication.

Taylor JM

Cold Spring Harbor perspectives in medicine 2015; (5(11)).

Federal Bureau of Prisons clinical pharmacy program improves patient A1C.

Bingham JT, Mallette JJ

Journal of the American Pharmacists Association : JAPhA 2016; (56(2)):173-7.

Chronic Hepatitis D; at a Standstill?

Rizzetto M

Digestive diseases (Basel, Switzerland) 2016; (34(4)):303-7 doi:10.1159/000444467.

Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options.

Lempp FA, Ni Y, Urban S

Nature reviews. Gastroenterology & hepatology 2016; (13(10)):580-9 doi:10.1038/nrgastro.2016.126.

Letter: changes in FIB-4 cut-off points for viral hepatitis - authors' reply.

Surana P, Takyar V, Koh C

Alimentary pharmacology & therapeutics 2017; (45(7)):1008-1009 doi:10.1111/apt.13974.

Delta hepatitis: Toward improved diagnostics.

Kamili S, Drobeniuc J, Mixson-Hayden T, Kodani M

Hepatology (Baltimore, Md.) 2017; (66(6)):1716-1718 doi:10.1002/hep.29564.

Quantification of serum markers of hepatitis B (HBV) and Delta virus (HDV) infections in patients with chronic HDV infection.

Ricco G, Popa DC, Cavallone D, et al.

Journal of viral hepatitis 2018; (25(8)):911-919 doi:10.1111/jvh.12895.

The experience of patients participating in a small randomised control trial that explored two different interventions to reduce anxiety prior to an MRI scan.

Tugwell-Allsup J, Pritchard AW

Radiography (London, England : 1995) 2018; (24(2)):130-136 doi:10.1016/j.radi.2017.11.001.

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.

Journal of hepatology 2018; (69(1)):182-236 doi:10.1016/j.jhep.2018.03.019.

Epidemiology and phylogenetic analysis of hepatitis D virus infection in Australia.

Jackson K, MacLachlan J, Cowie B, et al.

Internal medicine journal 2018; (48(11)):1308-1317 doi:10.1111/imj.13967.

Hepatitis D Viremia Among Injection Drug Users in San Francisco.

Mahale P, Aka PV, Chen X, et al.

The Journal of infectious diseases 2018; (217(12)):1902-1906 doi:10.1093/infdis/jiy157.

Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir.

Brancaccio G, Fasano M, Grossi A, et al.

Alimentary pharmacology & therapeutics 2019; (49(8)):1071-1076 doi:10.1111/apt.15188.

Characterization of hepatitis delta virus strains spreading in Abuja, Nigeria.

Ifeorah IM, Faleye TOC, Bakarey AS, et al.

Journal of medical virology 2019; (91(9)):1688-1692 doi:10.1002/jmv.25503.

Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta.

Deterding K, Wedemeyer H

AIDS reviews 2019; (21(3)):126-134 doi:10.24875/AIDSRev.19000080.

Treatment of chronic hepatitis due to hepatitis B and hepatitis delta virus coinfection.

Brancaccio G, Gaeta GB

International journal of antimicrobial agents 2019; (54(6)):697-701 doi:10.1016/j.ijantimicag.2019.09.012.

Vibration-controlled transient elastography for the detection of cirrhosis in chronic hepatitis D infection.

Da BL, Surana P, Takyar V, et al.

Journal of viral hepatitis 2020; (27(4)):428-436 doi:10.1111/jvh.13235.

The Delta-4 fibrosis score (D4FS): A novel fibrosis score in chronic hepatitis D.

Da BL, Surana P, Kleiner DE, et al.

Antiviral research 2020; (174()):104691 doi:10.1016/j.antiviral.2019.104691.

Editorial: rapid disease progression in hepatitis delta-can we turn the tide? Authors' reply.

Palom A, Riveiro-Barciela M, Buti M,

Alimentary pharmacology & therapeutics 2020; (51(1)):174-175 doi:10.1111/apt.15558.

Hepatitis delta genotype 5 is associated with favourable disease outcome and better response to treatment compared to genotype 1.

Spaan M, Carey I, Bruce M, et al.

Journal of hepatology 2020; (72(6)):1097-1104 doi:10.1016/j.jhep.2019.12.028.

Perceptions and Attitudes Towards Clinical Pharmacy Services and Their Impact on The Management of Cancer in Taif, Saudi Arabia.

Kabel AM, Bakr MM, Alshanbari AM, et al.

Asian Pacific journal of cancer prevention : APJCP 2020; (21(2)):531-538 doi:10.31557/APJCP.2020.21.2.531.

Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg.

Shekhtman L, Cotler SJ, Hershkovich L, et al.

Scientific reports 2020; (10(1)):7837 doi:10.1038/s41598-020-64122-0.

The genetic landscape of hepatitis delta virus infection.

Bigogno CM, Falahieh RR, Ho KMA, et al.

Clinical medicine (London, England) 2020; (20(Suppl 2)):s101 doi:10.7861/clinmed.20-2-s101.

Viral Hepatitis Other than A, B, and C: Evaluation and Management.

Cheung A, Kwo P

Clinics in liver disease 2020; (24(3)):405-419 doi:10.1016/j.cld.2020.04.008.

Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta.

Roulot D, Brichler S, Layese R, et al.

Journal of hepatology 2020; (73(5)):1046-1062 doi:10.1016/j.jhep.2020.06.038.

Murine hepatocytes do not support persistence of Hepatitis D virus mono-infection in vivo.

Giersch K, Hermanussen L, Volz T, et al.

Liver international : official journal of the International Association for the Study of the Liver 2021; (41(2)):410-419 doi:10.1111/liv.14677.

[Solute carrier NTCP, a key actor in liver infections by hepatitis viruses and a promising antiviral target].

Verrier ER, Heydmann L, Baumert TF, Schuster C

Virologie (Montrouge, France) 2018; (22(1)):55-66 doi:10.1684/vir.2018.0716.

The changing context of hepatitis D.

Rizzetto M, Hamid S, Negro F

Journal of hepatology 2021; (74(5)):1200-1211 doi:10.1016/j.jhep.2021.01.014.

Assembly and infection efficacy of hepatitis B virus surface protein exchanges in 8 hepatitis D virus genotype isolates.

Wang W, Lempp FA, Schlund F, et al.

Journal of hepatology 2021; (75(2)):311-323 doi:10.1016/j.jhep.2021.03.025.

Intact plasma quantification of the large therapeutic lipopeptide bulevirtide.

Sauter M, Blank A, Stoll F, et al.

Analytical and bioanalytical chemistry 2021; (413(22)):5645-5654 doi:10.1007/s00216-021-03384-7.

Durable virological response and functional cure of chronic hepatitis D after long-term peginterferon therapy.

Hercun J, Kim GE, Da BL, et al.

Alimentary pharmacology & therapeutics 2021; (54(2)):176-182 doi:10.1111/apt.16408.

Is hepatitis delta underestimated?

Papatheodoridi M, Papatheodoridis GV

Liver international : official journal of the International Association for the Study of the Liver 2021; (41 Suppl 1()):38-44 doi:10.1111/liv.14833.

New therapies for hepatitis delta virus infection.

Loureiro D, Castelnau C, Tout I, et al.

Liver international : official journal of the International Association for the Study of the Liver 2021; (41 Suppl 1()):30-37 doi:10.1111/liv.14838.

One-quarter of chronic hepatitis D patients reach HDV-RNA decline or undetectability during the natural course of the disease.

Palom A, Sopena S, Riveiro-Barciela M, et al.

Alimentary pharmacology & therapeutics 2021; (54(4)):462-469 doi:10.1111/apt.16485.

The Impact of Pharmaceutical Care in Multidisciplinary Teams on Health Outcomes: Systematic Review and Meta-Analysis.

Ruiz-Ramos J, Hernández MH, Juanes-Borrego AM, et al.

Journal of the American Medical Directors Association 2021; (22(12)):2518-2526 doi:10.1016/j.jamda.2021.05.038.

Hepatitis delta virus: From infection to new therapeutic strategies.

Niro GA, Ferro A, Cicerchia F, et al.

World journal of gastroenterology 2021; (27(24)):3530-3542 doi:10.3748/wjg.v27.i24.3530.

Poor clinical and virological outcome of nucleos(t)ide analogue monotherapy in HBV/HDV co-infected patients.

Scheller L, Hilgard G, Anastasiou O, et al.

Medicine 2021; (100(28)):e26571 doi:10.1097/MD.0000000000026571.

Prevalence and severity of scanxiety in people with advanced cancers: a multicentre survey.

Bui KT, Kiely BE, Dhillon HM, et al.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2022; (30(1)):511-519 doi:10.1007/s00520-021-06454-9.

New Treatments for Chronic Hepatitis B Virus/Hepatitis D Virus Infection.

Sandmann L, Wedemeyer H

Clinics in liver disease 2021; (25(4)):831-839 doi:10.1016/j.cld.2021.06.011.

Hepatitis D Review: Challenges for the Resource-Poor Setting.

Lee AU, Lee C

Viruses 2021; (13(10)) doi:10.3390/v13101912.

[Delta hepatitis: Epidemiology, diagnostic, natural history and treatment].

Loureiro D, Castelnau C, Bed CM, Asselah T

La Revue de medecine interne 2022; (43(3)):160-169 doi:10.1016/j.revmed.2021.10.329.

Liver Transplantation for Hepatitis D Virus in the United States: A UNOS Study on Outcomes in the MELD Era.

Kushner T, Da BL, Chan A, et al.

Transplantation direct 2022; (8(1)):e1253 doi:10.1097/TXD.0000000000001253.

Endemicity and genetic diversity of Hepatitis delta virus among Pygmies in Cameroon, Central Africa.

Foupouapouognigni Y, Mfonkou JDT, Boyomo O, et al.

BMC research notes 2022; (15(1)):87 doi:10.1186/s13104-022-05976-7.

Review article: emerging insights into the immunopathology, clinical and therapeutic aspects of hepatitis delta virus.

Usai C, Gill US, Riddell AC, et al.

Alimentary pharmacology & therapeutics 2022; (55(8)):978-993 doi:10.1111/apt.16807.

Multiple Regions Drive Hepatitis Delta Virus Proliferation and Are Therapeutic Targets.

Zi J, Gao X, Du J, et al.

Frontiers in microbiology 2022; (13()):838382 doi:10.3389/fmicb.2022.838382.

Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a "real world" study.

Jachs M, Schwarz C, Panzer M, et al.

Alimentary pharmacology & therapeutics 2022; (56(1)):144-154 doi:10.1111/apt.16945.

Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment.

Stella L, Santopaolo F, Gasbarrini A, et al.

World journal of gastroenterology 2022; (28(21)):2251-2281 doi:10.3748/wjg.v28.i21.2251.

Clinical trials in hepatitis D virus: Measuring success.

Da BL

Hepatology (Baltimore, Md.) 2023; (77(6)):2147-2157 doi:10.1002/hep.32732.

A Review of HDV Infection.

Caviglia GP, Ciancio A, Rizzetto M

Viruses 2022; (14(8)) doi:10.3390/v14081749.

New actors come into play against hepatitis delta.

Riveiro-Barciela M, Palom A, Buti M

Revista espanola de enfermedades digestivas 2022; (114(12)):702-704 doi:10.17235/reed.2022.9050/2022.

Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D.

Palom A, Rando-Segura A, Vico J, et al.

JHEP reports : innovation in hepatology 2022; (4(10)):100547 doi:10.1016/j.jhepr.2022.100547.

[Efficacy and safety of bulevirtide in patients with chronic hepatitis D and compensated cirrhosis].

Bogomolov PO, Ivashkin VT, Bueverov AO, et al.

Terapevticheskii arkhiv 2021; (93(11)):1290-1299 doi:10.26442/00403660.2021.11.201163.

Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy.

Soriano V, Moreno-Torres V, Treviño A, et al.

Drug design, development and therapy 2023; (17()):155-166 doi:10.2147/DDDT.S379964.

Prevalence of HDV infection in people living with HIV: Data from a multicenter Italian cohort.

Nicolini LA, Menzaghi B, Ricci E, et al.

Frontiers in medicine 2023; (10()):1086012 doi:10.3389/fmed.2023.1086012.

Emerging drugs for hepatitis D.

Keskin O, Yurdaydin C

Expert opinion on emerging drugs 2023; (28(2)):55-66 doi:10.1080/14728214.2023.2205639.

Hepatitis Delta Virus Antigens Trigger Oxidative Stress, Activate Antioxidant Nrf2/ARE Pathway, and Induce Unfolded Protein Response.

Smirnova OA, Ivanova ON, Mukhtarov F, et al.

Antioxidants (Basel, Switzerland) 2023; (12(4)) doi:10.3390/antiox12040974.

Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: An analysis of the HIDIT-II trial.

Dinkelborg K, Kahlhöfer J, Dörge P, et al.

Liver international : official journal of the International Association for the Study of the Liver 2023; (43(8)):1663-1676 doi:10.1111/liv.15602.

Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference.

Ghany MG, Buti M, Lampertico P, et al.

Hepatology (Baltimore, Md.) 2023; (78(5)):1654-1673 doi:10.1097/HEP.0000000000000431.

HDV RNA Levels and Progression of Hepatitis Delta Infection: A 14 Year Follow Up Experience in Italy.

Mangia A, Squillante MM, Fraticelli F, et al.

Cells 2023; (12(10)) doi:10.3390/cells12101413.

HDV RNA assays: Performance characteristics, clinical utility, and challenges.

Wedemeyer H, Leus M, Battersby TR, et al.

Hepatology (Baltimore, Md.) 2025; (81(2)):637-650 doi:10.1097/HEP.0000000000000584.

Patient satisfaction survey of the "Healthy Heart" pharmaceutical care service - evaluation of pharmacy labelling with pharmaceutical pictograms.

Merks P, Religioni U, Jaguszewski M, et al.

BMC health services research 2023; (23(1)):962 doi:10.1186/s12913-023-09986-4.

HBsAg protein composition and clinical outcomes in chronic hepatitis D and variations across HBeAg-negative chronic HBsAg carriers.

Roade L, Riveiro-Barciela M, Pfefferkorn M, et al.

JHEP reports : innovation in hepatology 2023; (5(10)):100842 doi:10.1016/j.jhepr.2023.100842.

Triple Threat: HDV, HBV, HIV Coinfection.

Yen DW, Soriano V, Barreiro P, Sherman KE

Clinics in liver disease 2023; (27(4)):955-972 doi:10.1016/j.cld.2023.05.010.

Anti-HDV reflex testing in HBsAg-positive subjects: An efficacious strategy to identify HDV infection.

Cossiga V, Brusa S, Montalti R, et al.

Liver international : official journal of the International Association for the Study of the Liver 2024; (44(1)):148-154 doi:10.1111/liv.15746.

Hepatitis D Virus and HBsAg Dynamics in the era of new Antiviral Treatments.

Shekhtman L, Duehren S, Etzion O, et al.

Current gastroenterology reports 2023; (25(12)):401-412 doi:10.1007/s11894-023-00901-9.

Comparative effectiveness of seven interventions for chronic hepatitis D: a systematic review and network meta-analysis of randomized controlled trials.

Rong Y, Ju X, Sun P, Wang Y

BMC infectious diseases 2023; (23(1)):726 doi:10.1186/s12879-023-08718-7.

Interferon-Free Regimens and Direct-Acting Antiviral Agents for Delta Hepatitis: Are We There Yet?

Nemteanu R, Clim A, Hincu CE, et al.

Current issues in molecular biology 2023; (45(10)):7878-7890 doi:10.3390/cimb45100498.

Prevalence of hepatitis D virus infection among patients with chronic hepatitis B infection in a tertiary care centre in Thailand.

Ananchuensook P, Suksawatamnuay S, Thaimai P, et al.

Scientific reports 2023; (13(1)):22633 doi:10.1038/s41598-023-49819-2.

Non-Invasive Prediction Scores for Hepatitis B Virus- and Hepatitis D Virus-Infected Patients-A Cohort from the North-Eastern Part of Romania.

Grecu LI, Sultana C, Pavel-Tanasa M, et al.

Microorganisms 2023; (11(12)) doi:10.3390/microorganisms11122895.

Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis-A real-world case series.

Dietz-Fricke C, Degasperi E, Jachs M, et al.

Hepatology (Baltimore, Md.) 2024; (80(3)):664-673 doi:10.1097/HEP.0000000000000847.

The Forgotten Virus, Hepatitis D: A Review of Epidemiology, Diagnosis, and Current Treatment Strategies.

Khattak A, Vongsavath T, Haque L, et al.

Journal of clinical and experimental hepatology 2024; (14(5)):101395 doi:10.1016/j.jceh.2024.101395.

Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D.

Asselah T, Chulanov V, Lampertico P, et al.

The New England journal of medicine 2024; (391(2)):133-143 doi:10.1056/NEJMoa2314134.

Long-term outcome of hepatitis delta in different regions world-wide: Results of the Hepatitis Delta International Network.

Wranke A, Lobato C, Ceausu E, et al.

Liver international : official journal of the International Association for the Study of the Liver 2024; (44(9)):2442-2457 doi:10.1111/liv.16006.

Efficacy of Pegylated Interferon-alpha-2a in Chronic Hepatitis Delta: Experience from a Tertiary Care Hospital in Karachi.

Butt N, Usmani MT, Hussain R, et al.

Euroasian journal of hepato-gastroenterology 2024; (14(1)):51-55 doi:10.5005/jp-journals-10018-1431.

[Chronic HBV and HDV infection].

Rusignuolo G, Thimme R, Neumann-Haefelin C

Deutsche medizinische Wochenschrift (1946) 2024; (149(16)):948-954 doi:10.1055/a-2057-1840.

Clinical and economic value of bulevirtide in the treatment of chronic hepatitis D.

Buti M, Calleja JL, Rodríguez MÁ, et al.

Gastroenterologia y hepatologia 2025; (48(3)):502241 doi:10.1016/j.gastrohep.2024.502241.

Molecular Epidemiology of Hepatitis D Virus in the North-East Region of Romania.

Grecu LI, Pavel-Tanasa M, Matei L, et al.

Pathogens (Basel, Switzerland) 2024; (13(9)) doi:10.3390/pathogens13090793.

Frequency of hepatitis D virus with different hepatitis B virus serological markers and coinfections in hospital patients from Argentina: synchronous testing of anti-HDV antibodies and HDV RNA.

Giorgio M, Ramírez Ladino KA, López G, et al.

European journal of gastroenterology & hepatology 2025; (37(1)):70-76 doi:10.1097/MEG.0000000000002857.

The Changing Face of Hepatitis Delta Virus Associated Hepatocellular Carcinoma.

Cardoso MF, Machado MV

Cancers 2024; (16(22)) doi:10.3390/cancers16223723.

Laboratory development of an RNA quantitative RT-PCR assay reporting in international units for hepatitis D virus.

Osiowy C, Day J, Lee ER

Frontiers in microbiology 2024; (15()):1472826 doi:10.3389/fmicb.2024.1472826.

Hepatitis Delta Virus Testing, Prevalence, and Liver-Related Outcomes Among US Veterans With Chronic Hepatitis B.

Wong RJ, Yang Z, Jou JH, et al.

Gastro hep advances 2025; (4(3)):100575 doi:10.1016/j.gastha.2024.10.015.

Assessment of Response and Safety of Bulevirtide Treatment in Patients with Chronic Delta Virus Infection: The ARISTOTLE Pilot Observational Study.

Rinaldi L, Viganò M, Ciancio A, et al.

Viruses 2025; (17(2)) doi:10.3390/v17020251.

Comparing methods for plasma HDV RNA quantification in bulevirtide-treated and untreated patients with HDV.

Anolli MP, Uceda Renteria S, Degasperi E, et al.

JHEP reports : innovation in hepatology 2025; (7(3)):101299 doi:10.1016/j.jhepr.2024.101299.

Clinical trials for Hepatitis Delta Virus in the WHO African region: A neglected virus among neglected viruses.

Delphin M, Campbell J, Verrier ER, et al.

The Journal of infection 2025; (91(1)):106514 doi:10.1016/j.jinf.2025.106514.

Accurate quantification using the new RoboGene HDV RNA Quantification Kit 3.0: A European multicenter study.

Stelzl E, Berger A, Ciesek S, et al.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2025; (179()):105828 doi:10.1016/j.jcv.2025.105828.

Comparison of diagnostic performances of HDV-RNA quantification assays used in clinical practice: Results from a national quality control multicenter study.

Salpini R, Piermatteo L, Caviglia GP, et al.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2025; (180()):105850 doi:10.1016/j.jcv.2025.105850.

Prevalence, severity, and modifiable predictors of scanxiety in patients undergoing routine oncologic imaging: a prospective longitudinal study.

Shah MS, Memon JA, Malik U, et al.

Clinical imaging 2025; (128()):110634 doi:10.1016/j.clinimag.2025.110634.

Adenine Base Editing Potently Suppresses Hepatitis B Surface Antigen Expression and Inhibits Hepatitis D Virus Release.

Kumar A, Combe E, Smekalova EM, et al.

bioRxiv : the preprint server for biology 2026; doi:10.64898/2026.02.06.704371.